Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Services » Medical Or Nursing Services
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| SDC | SmileDirectClub, Inc. | -0.46% | 12.02 | 0.0% | $106.56m | |
| DVA | DaVita, Inc. | -0.70% | 84.06 | 3.1% | $102.05m | |
| NVTA | Invitae Corp. | -3.02% | 23.10 | 2.5% | $94.47m | |
| GH | Guardant Health, Inc. | 1.59% | 88.81 | 0.0% | $60.50m | |
| ONEM | 1Life Healthcare, Inc. | -2.00% | 24.00 | 0.0% | $50.16m | |
| AMED | Amedisys, Inc. | -0.05% | 194.03 | 11.5% | $39.85m | |
| CHE | Chemed Corp. | -0.34% | 485.59 | 10.1% | $38.11m | |
| LHCG | LHC Group, Inc. | -1.54% | 155.00 | 2.9% | $25.87m | |
| MD | MEDNAX, Inc. | -4.63% | 19.99 | 11.2% | $25.53m | |
| NEO | NeoGenomics, Inc. | -1.84% | 32.49 | 6.0% | $24.09m | |
| FMS | Fresenius Medical Care AG & Co. KGaA | -2.38% | 41.02 | 0.1% | $21.54m | |
| ACHC | Acadia Healthcare Co., Inc. | -0.11% | 35.00 | 27.2% | $20.41m | |
| NTRA | Natera, Inc. | -2.11% | 37.11 | 1.3% | $18.85m | |
| TVTY | Tivity Health, Inc. | -4.00% | 12.00 | 9.1% | $18.41m | |
| ENSG | The Ensign Group, Inc. | -0.97% | 51.20 | 5.8% | $13.79m |
Company Profile
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.